Thu, December 14, 2023
Wed, December 13, 2023
Tue, December 12, 2023
Mon, December 11, 2023
Sun, December 10, 2023
Fri, December 8, 2023
Thu, December 7, 2023
Wed, December 6, 2023

Gena Wang Maintained (VRTX) at Buy with Increased Target to $415 on, Dec 11th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-415-on-dec-11th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Gena Wang of Barclays, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $408 to $415 on, Dec 11th, 2023.

Gena has made no other calls on VRTX in the last 4 months.



There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 3 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Reiterated at Hold and Held Target at $373 on, Wednesday, November 22nd, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $364 on, Wednesday, November 8th, 2023
  • Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $347 on, Tuesday, November 7th, 2023


These are the ratings of the 4 analyists that currently disagree with Gena


  • Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $380 on, Tuesday, December 5th, 2023
  • Evan Seigerman of "BMO Capital" Maintained at Buy with Increased Target to $415 on, Tuesday, November 7th, 2023
  • Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $370 on, Tuesday, October 17th, 2023
  • Robyn Karnauskas of "Truist Securities" Reiterated at Strong Buy and Held Target at $456 on, Wednesday, October 4th, 2023

Publication Contributing Sources